| 2026 | Prognostic Impact of TP53 and RB1 Alterations in Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel | CANCER INVESTIGATION |
| 2026 | Revo-i VS Da Vinci in Robotic Partial Nephrectomy: First Human Comparison | JOURNAL OF ENDOUROLOGY |
| 2026 | Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guérin therapy | BMC MEDICINE |
| 2025 | Prognosis of Prostate Cancer With Mucinous Components: A Propensity Score-Matched Study
| Journal of Urologic Oncology |
| 2025 | Efficacy and Safety of Ifosfamide and Mesna in Metastatic Castration-Resistant Prostate Cancer after Taxane-Based Chemotherapy and Novel Hormonal Therapy Failure | Cancer research and treatment |
| 2025 | Usefulness of free PSA ratio to enhance detection of clinically significant prostate cancer in patients with PI-RADS<3 and PSA≤10
| PROSTATE INTERNATIONAL |
| 2025 | Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis
| CANCER SCIENCE |
| 2024 | Single-port robot-assisted pyeloplasty using the da Vinci SP system versus multi-port pyeloplasty: Comparison of outcomes and costs | Asian Journal of Surgery |
| 2024 | The Role of Local Prostate and Metastasis-Directed Radiotherapy in the Treatment of Oligometastatic Prostate Cancer | CANCERS |
| 2024 | The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial | TRIALS |
| 2024 | Effects of exercise during active surveillance for prostate cancer: A systematic review and meta-analysis | SUPPORTIVE CARE IN CANCER |
| 2024 | Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer | EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING |
| 2024 | A 23-Gene Prognostic Index Predicts Progression and Bacillus Calmette-Guérin Response in Non-muscle-invasive Bladder Cancer | EUROPEAN UROLOGY |
| 2024 | Clinical Validation of the Proenkephalin (PENK) Methylation Urine Test for Monitoring Recurrence of Non-muscle-invasive Bladder Cancer | EUROPEAN UROLOGY OPEN SCIENCE |
| 2024 | Frailty of Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review | WORLD JOURNAL OF MENS HEALTH |
| 2024 | Effectiveness of a Nurse-Led Mobile-Based Health Coaching Program for Patients With Prostate Cancer at High Risk of Metabolic Syndrome: Randomized Waitlist Controlled Trial | JMIR MHEALTH AND UHEALTH |
| 2024 | The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): A study protocol for a multi-center, prospective, randomized trial | Journal of Clinical Oncology |
| 2024 | Deciphering the Role of ERBB3 Isoforms in Renal Cell Carcinoma: A Comprehensive Genomic and Transcriptomic Analysis | MEDICINA-LITHUANIA |
| 2023 | Differences in clinical features between focal and extensive types of cystitis glandularis in patients without a previous history of urinary tract malignancy | Investigative and Clinical Urology |
| 2023 | Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial | ASIAN JOURNAL OF ANDROLOGY |
| 2023 | Phosphodiesterase-5 Inhibitor Use in Robot Assisted Radical Prostatectomy Patients Is Associated with Reduced Risk of Death: A Propensity Score Matched Analysis of 1,058 Patients | The World Journal of Men's Health |
| 2023 | A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy | INVESTIGATIVE AND CLINICAL UROLOGY |
| 2023 | Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression | CANCERS |
| 2023 | Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer | CLINICAL GENITOURINARY CANCER |
| 2023 | Bladder Preservation With Transurethral Tumor Resection and Intravesical BCG Instillation in Superficial Muscle-Invasive Bladder Cancer: A 10-Year Follow-up | Journal of Urologic Oncology |
| 2023 | External validation of yonsei nomogram predicting chronic kidney disease development after partial nephrectomy: An international, multicenter study | International Journal of Urology |
| 2023 | Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA | Clinical Cancer Research |
| 2023 | Androgen-Independent Prostate Cancer Is Sensitive to CDC42-PAK7 Kinase Inhibition | Biomedicines |
| 2022 | Noninvasive studies may have potential to replace cystoscopy in non-muscle invasive bladder cancer follow-up | Scientific Reports |
| 2022 | Intravesical Recurrence after Radical Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma Is Associated with Flexible Diagnostic Ureteroscopy, but Not with Rigid Diagnostic Ureteroscopy | Cancers |
| 2022 | Characteristics of BRCA2 Mutated Prostate Cancer at Presentation | International Journal of Molecular Sciences |
| 2022 | Optical genome mapping identifies clinically relevant genomic rearrangements in prostate cancer biopsy sample | CANCER CELL INTERNATIONAL |
| 2022 | Quality of life patterns and its association with predictors among non-muscle invasive bladder cancer survivors: A latent profile analysis | Asia-Pacific Journal of Oncology Nursing |
| 2022 | Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib) | Clinical Cancer Research |
| 2022 | Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial | The Lancet Oncology |
| 2022 | Evaluation of the Surgical Margin Threshold for Avoiding Recurrence after Partial Nephrectomy in Patients with Renal Cell Carcinoma | Yonsei Medical Journal |
| 2021 | Metabolic tumour volume on F-18-FDG PET/CT predicts extended pathological T stages in patients with renal cell carcinoma at staging | Scientific Reports |
| 2021 | Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype | PROSTATE CANCER AND PROSTATIC DISEASES |
| 2021 | Exercise participation, barriers, and preferences in Korean prostate cancer survivors | Ethnicity and Health |
| 2021 | Subcutaneous Interleukin-2 Monotherapy for Metastatic Renal Cell Carcinoma in Korean Patients | Korean Journal of Urological Oncology(대한비뇨기종양학술지) |
| 2021 | Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma | Cancer Research and Treatment |
| 2021 | Prognostic value of prostate volume in non-muscle invasive bladder cancer | Scientific Reports |
| 2021 | Revisiting extraprostatic extension based on invasion depth and number for new algorithm for substaging of pT3a prostate cancer | Scientific Reports |
| 2021 | Glycolysis on F-18 FDG PET/CT Is Superior to Amino Acid Metabolism on C-11 Methionine PET/CT in Identifying Advanced Renal Cell Carcinoma at Staging | CANCERS |
| 2021 | Clinical Outcomes After Urinary Diversion for Malignant Ureteral Obstruction Secondary to Non-urologic Cancer: An Analysis of 778 Cases | ANNALS OF SURGICAL ONCOLOGY |
| 2020 | Retzius-sparing robot-assisted radical prostatectomy versus open retropubic radical prostatectomy: a prospective comparative study with 19-month follow-up | Minerva Urologica e Nefrologica |
| 2020 | Scale-Up Evaluation of a Composite Tumor Marker Assay for the Early Detection of Renal Cell Carcinoma | DIAGNOSTICS |
| 2020 | Effect of different general anaesthetics on ventricular repolarisation in robot-assisted laparoscopic prostatectomy | ACTA ANAESTHESIOLOGICA SCANDINAVICA |
| 2020 | Muscle Characteristics Obtained Using Computed Tomography as Prognosticators in Patients with Castration-Resistant Prostate Cancer
| CANCERS |
| 2020 | Synergistic Antitumor Effects of Combined Treatment with HSP90 Inhibitor and PI3K/mTOR Dual Inhibitor in Cisplatin-Resistant Human Bladder Cancer Cells
| YONSEI MEDICAL JOURNAL |
http://orcid.org/0000-0002-8545-5797
(7404777694)
